Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFiscal year ending March 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥29,679 million+4.0%
Operating profit¥1,322 million+19.2%
Ordinary income¥1,343 million+687.0%
Net income¥1,027 million
Operating profit margin4.5 %
Results for the three months of the current quarter
Net Sales
¥7,863 million
Operating profit
¥450 million
Full-year earnings forecast
Fiscal Period CoveredFiscal year ending March 2027
Net Sales
¥30,000 million
Operating profit
¥1,500 million
Operating profit margin
5 %
Ordinary income
¥1,200 million
Net income
¥2,000 million
Dividend per share
¥50
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in sales of medical applications
- Recovery in aircraft applications in the second half
- Shift from foreign-exchange losses to gainsPrevious period−¥1,055 millionCurrent fiscal year+¥264 million
The company identifies the factors but does not state the amount attributable to each one.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rateUS$1 = ¥150.0
New initiatives
- Plan to sell the Singapore plantTimingDuring the fiscal year ending March 2027
Segment results
Japan
Net Sales
Fiscal year ending March 2025¥9,095 million
Fiscal year ending March 2026¥9,203 million
Segment profit
Fiscal year ending March 2025¥222 million
Fiscal year ending March 2026¥255 million
Americas
Net Sales
Fiscal year ending March 2025¥5,410 million
Fiscal year ending March 2026¥6,014 million
Segment profit
Fiscal year ending March 2025¥192 million
Fiscal year ending March 2026¥276 million
Europe
Net Sales
Fiscal year ending March 2025¥3,399 million
Fiscal year ending March 2026¥3,543 million
Segment profit
Fiscal year ending March 2025¥150 million
Fiscal year ending March 2026¥80 million
Asia
Net Sales
Fiscal year ending March 2025¥10,627 million
Fiscal year ending March 2026¥10,918 million
Segment profit
Fiscal year ending March 2025¥544 million
Fiscal year ending March 2026¥700 million
Capital expenditures
¥1,556 million
Annual Dividend
Fiscal year ending March 2026¥35
Forecast for the fiscal year ending March 2027¥50
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥29,679 million (YoY +4.0%) |
| Operating profit | ¥1,322 million (YoY +19.2%) |
| Ordinary income | ¥1,343 million (YoY +687.0%) |
| Net income | ¥1,027 million |
| Operating profit margin | 4.5 % |
| Results for the three months of the current quarter | Net Sales ¥7,863 million / Operating profit ¥450 million |
| Full-year earnings forecast | Fiscal Period Covered Fiscal year ending March 2027 / Net Sales ¥30,000 million / Operating profit ¥1,500 million / Operating profit margin 5 % / Ordinary income ¥1,200 million / Net income ¥2,000 million / Dividend per share ¥50 |
| Segment results | Japan Net Sales Fiscal year ending March 2025 ¥9,095 million / Fiscal year ending March 2026 ¥9,203 million / Segment profit Fiscal year ending March 2025 ¥222 million / Fiscal year ending March 2026 ¥255 million / Americas Net Sales Fiscal year ending March 2025 ¥5,410 million / Fiscal year ending March 2026 ¥6,014 million / Segment profit Fiscal year ending March 2025 ¥192 million / Fiscal year ending March 2026 ¥276 million / Europe Net Sales Fiscal year ending March 2025 ¥3,399 million / Fiscal year ending March 2026 ¥3,543 million / Segment profit Fiscal year ending March 2025 ¥150 million / Fiscal year ending March 2026 ¥80 million / Asia Net Sales Fiscal year ending March 2025 ¥10,627 million / Fiscal year ending March 2026 ¥10,918 million / Segment profit Fiscal year ending March 2025 ¥544 million / Fiscal year ending March 2026 ¥700 million |
| Breakdown of Factors Affecting the Change | Factors Increase in sales of medical applications / Amount Not disclosed, Factors Recovery in aircraft applications in the second half / Amount Not disclosed, Factors Shift from foreign-exchange losses to gains / Previous period −¥1,055 million / Current fiscal year +¥264 million |
| Assumptions Underlying the Business Outlook | Exchange rate US$1 = ¥150.0 |
| Annual Dividend | Fiscal year ending March 2026 ¥35 / Forecast for the fiscal year ending March 2027 ¥50 |
| Capital expenditures | ¥1,556 million |
| New initiatives | Measures Plan to sell the Singapore plant / Timing During the fiscal year ending March 2027 |
Items this document does not state (16)
Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, continued strong performance in medical applications, mainly in Europe and the United States, and a recovery in aircraft applications from the second half drove increases in revenue and operating income. Foreign exchange losses arising from the revaluation of assets and liabilities held by the Company turned from a loss of ¥1,055 million in the previous fiscal year into a gain of ¥264 million in the current fiscal year, bringing ordinary income and net income back into the black. The net income forecast for the fiscal year ending March 2027 includes a gain on the planned sale of the Singapore plant during the fiscal year, among other items.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.